Holen Sie sich die Stockscreener-App
3.79
3.84%
0.14
Handel nachbörslich:
3.79
Schlusskurs vom Vortag:
$3.65
Offen:
$3.7
24-Stunden-Volumen:
434.51K
Relative Volume:
0.82
Marktkapitalisierung:
$1.18B
Einnahmen:
$563.46M
Nettoeinkommen (Verlust:
$27.92M
KGV:
39.32
EPS:
0.0964
Netto-Cashflow:
$-146.33M
1W Leistung:
+15.20%
1M Leistung:
-5.49%
6M Leistung:
-55.83%
1J Leistung:
-55.41%
1-Tages-Spanne:
$3.69
$3.925
1-Wochen-Bereich:
$3.27
$3.925
52-Wochen-Spanne:
$3.03
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.79 | 1.14B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-11-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-14 | Eingeleitet | UBS | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Herabstufung | Citigroup | Buy → Sell |
| 2022-07-26 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Alvotech Aktie (ALVO) Neueste Nachrichten
Alvotech (NASDAQ:ALVO) Trading Up 7.2%Here's What Happened - MarketBeat
ETFs Investing in Alvotech Stocks - TradingView
Institution Moves: Is Alvotech stock overvalued or fairly pricedMarket Movers & Weekly High Return Forecasts - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Stock Rating Lowered by Wall Street Zen - MarketBeat
ALVO Should I Buy - Intellectia AI
ALVO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag - MSN
Alvotech (ALVO) revenue surges 21% year-over-year in 2025 - MSN
ALVO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alvotech Earnings Call: Growth Momentum Meets FDA Risk - The Globe and Mail
Alvotech (ALVO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alvotech (ALVO) Revenue Surges 21% Year-Over-Year in 2025 - Insider Monkey
Does Alvotech’s (ALVO) Reaffirmed 2026 Revenue Target Redefine Its Biosimilar Strategy Narrative? - Sahm
Alvotech’s comprehensive biosimilars platform presents an uneven risk-reward profile as the market factors in the FDA approval challenge - Bitget
Alvotech : Transactions of Managers and Closely Associated Persons - marketscreener.com
Alvotech : Managers’ transactionsManager Transaction NotificationATP ehf.EN - marketscreener.com
Alvotech : Managers' transactionsALVOTECH - MarketScreener
Alvotech Files Annual Report with the SEC - The Manila Times
Alvotech Files Annual Report 2025 with the U.S. SEC - Quiver Quantitative
Alvotech files Annual Report with the SEC - GlobeNewswire
Alvotech Publishes 2025 Annual Report - globenewswire.com
Alvotech (NASDAQ: ALVO) turns 2025 profit while managing heavy debt and FDA CRLs - Stock Titan
Alvotech (NASDAQ:ALVO) Shares Up 5.3%Time to Buy? - MarketBeat
Short Interest in Alvotech (NASDAQ:ALVO) Drops By 17.0% - marketbeat.com
Alvotech Stock: Biosimilar Innovator Positions for U.S. Market Expansion Amid Global Growth Push - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Alvotech Faces Weak Start with 6.54% Gap Down Amid Market Concerns - Markets Mojo
Retail Trends: What is the dividend yield of Alvotech Equity WarrantMarket Rally & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Fed Meeting: Whats the fair value of Alvotech stock2026 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position - Yahoo Finance
Alvotech Shares Plunge to New 52-Week Low at $3.03 - Markets Mojo
Alvotech stock hits new 52-week low on UBS price target cut to $6 amid biosimilar launch delays - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Alvotech price target lowered to $4 from $5 at Barclays - TipRanks
Alvotech Drops 14% Amid Prevailing Negative Market Sentiment - Bitget
Alvotech price target lowered to $4 from $8 at Deutsche Bank - TipRanks
Barclays Lowers Price Target for Alvotech (ALVO) to $4.00, Maint - GuruFocus
Alvotech Stock Hits Day Low of $3.44 Amid Price Pressure - marketsmojo.com
UBS cuts Alvotech stock price target on delayed biosimilar launches By Investing.com - Investing.com South Africa
UBS cuts Alvotech stock price target on delayed biosimilar launches - Investing.com UK
Alvotech (ALVO) Maintains 'Buy' Rating with Lowered Price Target by UBS | ALVO Stock News - GuruFocus
UBS Group Cuts Alvotech (NASDAQ:ALVO) Price Target to $6.00 - MarketBeat
Barclays Has Lowered Expectations for Alvotech (NASDAQ:ALVO) Stock Price - MarketBeat
UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating - marketscreener.com
Deutsche Bank Maintains Alvotech(ALVO.US) With Hold Rating, Cuts Target Price to $4 - 富途牛牛
UBS Maintains Alvotech(ALVO.US) With Buy Rating, Maintains Target Price $6 - news.futunn.com
Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating - marketscreener.com
Alvotech: Regulatory Setbacks Priced In, Biosimilar Strength Supports Buy Rating Despite Lowered Target - TipRanks
UBS Maintains Alvotech(ALVO.US) With Buy Rating, Cuts Target Price to $6 - 富途牛牛
Alvotech SA stock hits 52-week low at $3.42 amid challenging year - Investing.com Canada
Finanzdaten der Alvotech-Aktie (ALVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):